Introduction
============

Clear cell renal cell carcinoma (ccRCC) accounts for 70--80% of all RCC and it is closely associated with von Hippel-Lindau tumor suppressor gene mutations ([@b1-ol-0-0-11780],[@b2-ol-0-0-11780]). RCC comprises of a wide group of chemotherapy-resistant diseases that can be distinguished by histopathological features and underlying gene mutations ([@b2-ol-0-0-11780]); however, the variable biological behavior of early ccRCC usually leads to a failed diagnosis ([@b3-ol-0-0-11780]). The molecular pathogenesis of ccRCC also remains unclear. It is of great clinical importance to fully understand the pathogenesis of ccRCC, at this would lead to the identification of reliable prognostic biomarkers and appropriate treatment selection.

The aberrant expression of coding genes and long non-coding RNAs (lncRNA) is usually associated with the emergence and development of various types of cancers, such as lung adenocarcinoma, ovarian cancer and ccRCC, and lncRNAs could serve as potential diagnostic markers ([@b4-ol-0-0-11780]--[@b8-ol-0-0-11780]). It is well known that ccRCC is associated with the following: Dysregulated oxidative phosphorylation, amino acid metabolism and oncogenic metabolism, such as the downregulation of genes involved in the tricarboxylic acid cycle, decreased AMP-activated kinase and levels of PTEN protein, upregulation of the pentose phosphate pathway and glutamine transporter genes and increased acetyl-Coenzyme A carboxylase protein levels ([@b2-ol-0-0-11780],[@b9-ol-0-0-11780],[@b10-ol-0-0-11780]). lncRNAs are non-coding RNAs of \>200 nucleotides in length, and numerous ccRCC-associated lncRNAs have been identified and applied as potential prognostic and diagnostic biomarkers, such as metastasis-associated lung adenocarcinoma transcript 1 and nuclear paraspeckle assembly transcript 1 ([@b11-ol-0-0-11780]--[@b13-ol-0-0-11780]). Despite considerable progress, the prognostic roles of coding genes and lncRNAs in ccRCC, and the underlying mechanisms remain poorly understood. Further functional investigation is required to explore more ccRCC-associated coding genes and lncRNAs, and to verify their functional mechanisms with respect to the prognosis in patients with ccRCC.

Disease progression is usually mediated by multiple relevant genes rather than by a single gene ([@b14-ol-0-0-11780]). It would be useful for both healthcare providers and patients to develop risk assessment tools that could detect populations at high risk of a disease and inform clinical decisions regarding treatment ([@b15-ol-0-0-11780]). Compared with the extensive application of risk assessment tools for various types of cancer, such as gastric cancer, hepatocellular carcinoma and prostate cancer ([@b15-ol-0-0-11780]--[@b17-ol-0-0-11780]), risk assessment tools for ccRCC remain scant. The disease-free survival of patients with localized ccRCC has mostly been predicted using an immunohistochemistry-based molecular signature of five markers, including Ki-67, p53, endothelial vascular endothelial growth factor receptor (VEGFR)-1, epithelial VEGFR-1, and epithelial vascular endothelial growth factor (VEGF)-D ([@b18-ol-0-0-11780]), and prognosis in patients with ccRCC has been assessed using expression-based mRNA and non-coding RNA signatures ([@b11-ol-0-0-11780],[@b19-ol-0-0-11780]--[@b21-ol-0-0-11780]). Therefore, further risk assessment tools for ccRCC are required.

The present study analyzed large quantities of gene expression and corresponding clinical data of patients with ccRCC downloaded from The Cancer Genome Atlas (TCGA) and European Bioinformatics Institute (EBI) Array databases in the public domain. Differentially expressed RNAs (DERs) were identified and an optimal prognosis prediction model was constructed after comparing models based on the expression levels or status of prognostic DERs. The reliability of the prognostic prediction model was validated in two independent datasets. Furthermore, possible biological functions of the prognostic DERs in the pathogenesis of ccRCC were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The present study aimed to identify potential clinical diagnostic markers for ccRCC and to determine the possible pathogenesis of ccRCC.

Materials and methods
=====================

### Data sources and preprocessing

The RNA expression profiles of ccRCC samples downloaded on April 5, 2019, from TCGA database (<https://gdc-portal.nci.nih.gov/>) were generated on an Illumina HiSeq 2000 RNA Sequencing platform. A total of 526 ccRCC tumor samples accompanied by relevant information about clinical survival were randomly assigned to either a training or validation set (n=263 in each). [Table I](#tI-ol-0-0-11780){ref-type="table"} shows the clinicopathological characteristics and prognostic information about the samples in the training, validation and training + validation (entire) sets. A gene expression dataset of patients with ccRCC (E-TABM-3267) ([@b22-ol-0-0-11780]), assessed on 22 January 2015 and last updated on 27 September 2018, was downloaded from the EBI Array database (<https://www.ebi.ac.uk/arrayexpress/>) ([@b23-ol-0-0-11780]) based on an Affymetrix GeneChip Human Gene 1.0 ST Array platform. The E-TABM-3267 dataset included 53 ccRCC tumor tissue samples with accompanying survival information, and served as an independent validation dataset.

### Screening DERs in ccRCC samples

#### Annotation and identification of lncRNAs and mRNAs

According to probe location and ID provided in the downloaded annotation platform, lncRNAs and mRNAs in TCGA and EBI sets were annotated and identified from the Human Genome Organization Gene Nomenclature Committee (HGNC) database (<http://www.genenames.org/>), which comprises of 4,112 lncRNAs and 19,201 protein-encoding genes ([@b24-ol-0-0-11780]).

#### Screening of significant DERs

The 263 patients in the training set were classified as having a less favorable (overall survival time, \<36 months) or a favorable (overall survival time, \>60 months) prognosis. Significant DERs between the two prognostic groups in the training set were screened using the limma package (v3.34.7; <http://bioconductor.org/packages/release/bioc/html/limma.html>) ([@b25-ol-0-0-11780]) in R language ([@b26-ol-0-0-11780]) (v3.4.1). A false discovery rate (FDR) \<0.05 and log 2-fold change (log~2~FC) \>0.5 were set as thresholds for determining significant DERs. Volcano plots of the DERs were created using the ggplot2 ([@b27-ol-0-0-11780]) package (v2.2.1) in R 3.4.1. Subsequently, pheatmap (v1.0.8; <https://cran.r-project.org/web/packages/pheatmap/index.html>) ([@b28-ol-0-0-11780]) in R 3.4.1 was used to analyze two-way hierarchical clustering of samples with a centered Pearson correlation algorithm based on DER expression.

### Construction of prognostic model

#### Screening prognostic DERs

Based on the DERs screened in the aforementioned step, overall survival time in the training set was assessed via univariate and multivariate Cox regression analyses using a survival package (v2.41-1; <http://bioconductor.org/packages/survivalr/>) ([@b29-ol-0-0-11780]) in R 3.4.1 to identify DEmRNAs and DElncRNAs with independent prognostic values, with log-rank P\<0.05 as the cutoff of significance.

#### Screening optimal DER combinations

The Least Absolute Shrinkage And Selection Operator (LASSO) Cox regression model ([@b30-ol-0-0-11780]) of penalized package v0.9.50 ([@b31-ol-0-0-11780]) (<https://cran.r-project.org/web/packages/penalized/index.html>) in R 3.4.1 was used to uncover the optimal combinations of the aforementioned prognostic DEmRNAs and DElncRNAs. The optimized parameter 'lambda' was generated via the cross-validation likelihood (cvl) of 1,000 measurements.

#### Diverse risk assessment models constructed based on optimal mRNAs or lncRNAs

Two categories of risk assessment models were constructed using multivariate Cox regression coefficients of the optimal combinations of DEmRNAs or DElncRNAs.

#### Risk prediction models based on mRNA or lncRNA status

The cut-off values for amounts of optimal DEmRNA and DElncRNA expression were calculated using the X-Tile Bio-Information Tool ([@b32-ol-0-0-11780]) (<https://medicine.yale.edu/lab/rimm/research/software.aspx>). The Monte-Carlo value P\<0.05 was set as the criterion to determine the optimal cut-off for RNA expression. The status of RNA expression in the samples was defined according to the cut-off for each RNA; RNA expression \> cut-off or \< cut-off was defined as status 1 or 0, respectively. Two risk assessment models of status risk score were established using a linear combination of expression status of the optimal mRNAs or lncRNAs, weighted by regression coefficients to calculate status risk scores for each sample according to the following formula: β~RNAn~ × Status~RNAn~, where β~RNAn~ and Status~RNAn~ represent the regression coefficient and status variable of RNAn, respectively.

#### Risk prediction models based on expression levels of mRNAs or lncRNAs

Two risk prediction models of expression risk score were constructed based on the expression levels of optimal mRNA or lncRNA, and expression risk scores for all samples were calculated as follows: ∑β~RNAn~ × Expression~RNAn~, where β~RNAn~ and Expression~RNAn~ represent the regression coefficient and the amount of RNAn expression, respectively.

#### Evaluation and comparison of diverse risk prediction models

Samples in the training set were divided into high- and low-risk groups for each of the four prognosis prediction models, with the median risk score as the demarcation point. Associations between risk models and overall survival time were evaluated using Kaplan-Meier curves in the survival package (v2.41--1) in R 3.4.1. The sensitivity and specificity of risk scores to predict the overall survival time of patients were evaluated using receiver operating characteristic (ROC) curves. The predictive capability of these models was authenticated using the validation, entire and independent validation (E-TABM-3267) datasets. The optimal model was that with the greatest power to predict the prognosis in patients with ccRCC.

### Establishment of a survival nomogram based on independent prognostic factors and the fittest risk score model

#### Screening independent prognostic clinical factors

Independent prognostic clinical factors were screened in samples in the training, validation and entire sets via univariate and multivariate Cox regression analysis using the survival package (v2.41--1) in R3.4.1. Log-rank values with P\<0.05 were chosen as thresholds for identifying significant prognostic clinical factors. Pathological stage of ccRCC was defined according to the 1997 TNM staging system ([@b33-ol-0-0-11780]). The tumors were graded following the Fuhrman nuclear grading system ([@b34-ol-0-0-11780]). Normal platelet count was defined as 100--300×10^9^/l; elevated platelet count, \>300×10^9^/l; low platelet count, \<300×10^9^/l. Normal serum calcium levels are 2.25--2.75 mmol/l, elevated levels, \>2.75 mmol/l and low levels \<2.25 mmol/l. Normal white cell count was defined as 4.0--10.0×10^9^/l, elevated count was \>10.0×10^9^/l and low count was \<4.0×10^9^/l.

#### Construction of nomograms for 3- and 5-year survival probability

Associations between independent prognostic factors and prognosis were further analyzed as follows. Risk scores from the optimal prognostic prediction model were combined with the identified independent prognostic factors, and nomograms were constructed for 3- and 5-year survival probability using the rms package (v5.1--2) ([@b35-ol-0-0-11780],[@b36-ol-0-0-11780]) in R 3.4.1 (<https://cran.r-project.org/web/packages/rms/index.html>). Nomograms enable the visualization of regression equations. Scoring criteria are formulated by the magnitude of the regression coefficients of all independent variables. Scales of each independent variable are scored, and a total score can be estimated for each sample. The probability and outcome for each sample can then be calculated using a conversion function between the score and the probability that the outcome will occur ([@b37-ol-0-0-11780]). Probabilities derived from nomograms were used to evaluate and predict associations between independent prognostic factors and the prognosis of targets.

#### Functional analysis of DE genes (DEGs) in high-and low-risk groups in the entire set

Samples in the entire set were divided into high- and low-risk groups according to risk scores obtained from the fittest prognostic prediction model. Differences in the expression matrix of genes between the high- and low-risk groups were investigated using the limma package (v3.34.7) in R 3.4.1. FDR \<0.05 and log~2~FC \>0.263 were set as the threshold for identifying DEGs, and a volcano plot of significant DEGs was created using the ggplot2 package in R 3.4.1. Gene Ontology (GO) of biological processes and KEGG pathway enrichment analysis of the identified DEGs were performed using the clusterProfiler package (v3.6.0) in R 3.4.1 language ([@b38-ol-0-0-11780]) (<http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html>). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of DERs

#### Annotation of lncRNAs and mRNAs

According to probe location provided in the downloaded platforms, 19,021 mRNAs and 376 lncRNAs were annotated in TCGA set, and 18,007 mRNAs and 402 lncRNAs were annotated in E-TABM-3267 using the HGNC database. After removing the mRNAs and lncRNAs with a value of 0 in all samples, the two datasets had 17,097 mRNAs and 376 lncRNAs in common (data not shown).

#### Screening DERs

The RNA expression profiles of 526 ccRCC tumor samples were downloaded from TCGA database with corresponding clinical data. These samples were randomly and equally divided into training (n=263) and testing (n=263) sets. Among the 263 ccRCC cancer samples in the training set, the prognosis of 53 samples was defined as less favorable and that of 63 samples was defined as favorable. A total of 451 significant DERs with FDR \<0.05 and log~2~FC \>0.5 were identified between the two prognoses groups from the volcano plot generated using the limma package ([Fig. 1A](#f1-ol-0-0-11780){ref-type="fig"}). These DERs comprised 404 (22 downregulated and 382 upregulated) mRNAs and 47 (three downregulated and 44 upregulated) lncRNAs ([Fig. 1A](#f1-ol-0-0-11780){ref-type="fig"}). Two-way hierarchical clustering heatmaps showed that the samples clustered into two groups ([Fig. 1B](#f1-ol-0-0-11780){ref-type="fig"}).

### Construction of prognostic models

#### Screening independent prognostic DER

Univariate Cox regression analysis was used to screen 269 prognostic DERs, including 233 mRNAs and 36 lncRNAs from the 451 DERs identified according to the overall survival time of patients in the aforementioned step. Multivariate Cox regression analysis then selected 44 mRNAs and 15 lncRNAs as independent prognostic factors (data not shown).

#### Screening optimal DER combinations

Using the expression values of the identified 44 mRNAs and 15 lncRNAs of independent prognostic values as input, the combination of predictive mRNAs or lncRNAs was further optimized and identified using the Cox regression model based on LASSO regularization regression algorithm in the penalized package. When the maximum value of cvl was −491.8333, the lambda value was 17.3155, obtaining an optimal combination of 10 mRNAs comprising anterior gradient homolog 3 (*AGR3*), granulocyte-macrophage colony-stimulating factor (*CSF2*), galactose 3-O-sulfotransferase (*GAL3ST2*), immunoglobulin λ-like polypeptide 1 (*IGLL1*), plasminogen (*PLG*), serum amyloid A1 (*SAA1*), suprabasin (*SBSN*), SRY-type HMG box transcription factor 2 (*SOX2*), whey acidic protein (WAP) four-disulfide core domain protein (*WFDC13*) and zinc finger of the cerebellum family member 2 (*ZIC2*) ([Fig. 2A](#f2-ol-0-0-11780){ref-type="fig"}). When the cvl reached the maximum value of −490.4969, lambda was 65.3960, and an optimal combination of 10 significant lncRNAs was retrieved, comprising of collagen 18A1 antisense RNA 1 (COL18A1-AS1), elongation of very long-chain fatty acid 2 antisense RNA 1 (ELOVL2-AS1), long intergenic non-protein coding RNA 189 (LINC00189), LINC00470, LINC00652, LINC00896, microRNA 205 host gene (MIR205HG), T cell leukemia/lymphoma 6 (TCL6), transcription factor AP-2 α antisense RNA (TFAP2A-AS1) and uroplakin 1A antisense RNA 1 (UPK1A-AS1) ([Fig. 2B](#f2-ol-0-0-11780){ref-type="fig"}). Regression coefficients, P-values, hazard ratios (HRs) and 95% CIs of the 10 significant lncRNAs and 10 significant mRNAs derived from the LASSO Cox regression model are listed in [Table II](#tII-ol-0-0-11780){ref-type="table"}. P-values of all the 10 lncRNAs and 10 mRNAs were all \<0.05.

#### Construction of risk prediction models based on optimal combinations of 10 mRNAs or 10 lncRNAs

Various types of risk prediction models were constructed based on the regression coefficients of the optimal combinations of the aforementioned 10 prognostic mRNAs or lncRNAs ([Table II](#tII-ol-0-0-11780){ref-type="table"}).

#### Risk prediction models based on mRNA expression status (I)

Associations between expression levels of the identified combinations of 10 DElncRNAs or 10 DEmRNAs in samples and overall survival time were analyzed in the training set using the X-Tile Bio-Informatics Tool. [Table II](#tII-ol-0-0-11780){ref-type="table"} shows the cut-off values for the expression levels of each DElncRNA or DEmRNA.

According to the cut-off value of each RNA, the status of samples with lower and higher expression was set to 0 and 1, respectively. Consequently, the following prediction model based on the status of 10 mRNAs or 10 lncRNAs was constructed: mRNA Status risk score = 0.0148287 × Status~AGR3~ + (0.0042776) × Status~CSF2~ + (0.0076842) × Status~GAL3ST2~+ (0.0045121) × Status~IGLL1~ + (−0.008533) × Status~PLG~ + (0.0193154) × Status~SAA1~ + (0.0155634) × Status~SBSN~ + (0.0011085) × Status ~SOX2~ + (0.0011551) × Status~WFDC13~ + (0.0358394) × Status~ZIC2~; lncRNA Status risk score = −0.058594 × Status~COL18A1-AS1~ + (0.0155223) × Status~ELOVL2-AS1~ + (0.0112113) × Status~LINC00189~ + (0.036526) × Status~LINC00470~ + (0.0190087) × Status~LINC00652~ + (0.0707072) × Status~LINC00896~ + (0.0209242) × Status ~MIR205HG~ + (−0.081477) × Status~TCL6~+ (0.0910578) × Status~TFAP2A-AS1~+ (0.015775) × Status~UPK1A-AS1.~

#### Risk prediction models based on expression levels (II)

The following prediction models were created based on expression levels (Exprs) of the mRNAs or lncRNAs in the aforementioned step: mRNA Expression risk score = 0.0148287 × ExprsAGR3 + (0.0042776) × ExprsCSF2 + (0.0076842) × ExprsGAL3ST2 + (0.0045121) × ExprsIGLL1 + (−0.008533) × ExprsPLG + (0.0193154) × ExprsSAA1 + (0.0155634) × ExprsSBSN + (0.0011085) × ExprsSOX2 + (0.0011551) × ExprsWFDC13 + (0.0358394) × ExprsZIC2; lncRNA Expression risk score = −0.058594 × ExprsCOL18A1-AS1 + (0.0155223)x ExprsELOVL2-AS1 + (0.0112113) × ExprsLINC00189 + (0.036526) × ExprsLINC00470 + (0.0190087) × ExprsLINC00652 + (0.0707072)x ExprsLINC00896 + (0.0209242) × ExprsMIR205HG + (−0.081477) × ExprsTCL6 + (0.0910578) × ExprsTFAP2A-AS1+ (0.015775) × ExprsPK1A-AS1.

#### Effectiveness evaluation and comparison of prognosis prediction models

The predictive abilities of the four models were evaluated and compared among the training, validation, entire and E-MTAB-3267 (independent validation) sets ([Figs. 3](#f3-ol-0-0-11780){ref-type="fig"} and [4](#f4-ol-0-0-11780){ref-type="fig"}). The training \[lncRNAs-based status risk score: log-rank P=4.07×10^−9^; HR (95% CI), 3.885 (2.388--6.321); mRNAs-based status risk score: log-rank P=1.04×10^−10^; HR (95% CI), 4.653 (2.757--7.553)\], validation \[lncRNAs-based status risk score:log-rank P=9.58×10^−4^; HR (95% CI), 2.087 (1.329--3.278); mRNAs-based status risk score: log-rank P=2.27×10^−5^; HR (95% CI), 2.637 (1.654--4.203)\] and entire \[lncRNAs-based status risk score:log-rank P=5.41×10^−11^; HR (95% CI), 2.869 (2.064--3.989); mRNAs-based status risk score: log-rank P=2.73×10^−13^; HR (95% CI), 3.270 (2.336--4.578)\] sets were separated into a high-risk group (shorter overall survival time) and a low-risk group (longer overall survival time) using the status model based on the 10 lncRNAs or 10 mRNAs, respectively ([Fig. 3](#f3-ol-0-0-11780){ref-type="fig"}). However, the two status models could not dichotomize the E-MTAB-3267 set into two risk groups with significantly different overall survival time (log-rank P=5.14×10^−1^ for lncRNA and 6.20×10^−2^ for mRNA; [Fig. 3](#f3-ol-0-0-11780){ref-type="fig"}; [Table III](#tIII-ol-0-0-11780){ref-type="table"}). Furthermore, all four datasets exhibited significantly different overall survival time between the high- and low-risk groups determined using the 10 lncRNA expression model ([Fig. 4A](#f4-ol-0-0-11780){ref-type="fig"}): training set, log-rank P=6.33×10^−8^; HR (95% CI), 3.454 (2.145--5.563); validation set, log-rank P=7.41×10^−9^; HR (95% CI), 3.947 (2.389--6.521); entire set, log-rank P=1.37×10^−14^; HR (95% CI), 3.521 (2.503--4.955); E-MTAB-3267, log-rank P=3.83×10^−2^; HR (95% CI), 1.942 (1.025--3.678). Similar results were obtained using the 10 mRNA expression model ([Fig. 4B](#f4-ol-0-0-11780){ref-type="fig"}): training set, log-rank P=5.37×10^−10^; HR (95% CI), 4.315 (2.611--7.132); validation set, log-rank P=9.17×10^−6^; HR (95% CI), 2.816 (1.746--4.542); entire set, log-rank P=3.04×10^−14^; HR (95% CI), 3.513 (2.486--4.964); E-MTAB-3267, log-rank P=6.89×10^−3^; HR (95% CI), 2.404 (1.248--4.628). Additionally, [Figs. 3](#f3-ol-0-0-11780){ref-type="fig"} and [4](#f4-ol-0-0-11780){ref-type="fig"} show the ROC curves and areas under the ROC curves (AUC) of the four models for the training, validation, entire and E-MTAB-3267 sets. The aforementioned results suggested that the risk assessment model based on the expression levels of the 10 mRNAs yielded more significant or similar log-rank P-values, and higher or similar AUC values compared with the other three models in the four datasets. Therefore, this model was selected as the best prognostic model and was applied in further analyses.

#### Establishment of nomogram survival model with independent prognostic clinical factors and 10 DEmRNA expression risk scores

Independent clinical prognostic factors for ccRCC were analyzed using univariate and multivariate Cox regression analyses of the samples. [Table III](#tIII-ol-0-0-11780){ref-type="table"} shows that age, pathological stage and mRNA expression model risk score status were identified as independent prognostic factors in the training, validation and entire sets (P\<0.05). [Fig. 5](#f5-ol-0-0-11780){ref-type="fig"} shows the Kaplan-Meier curves of age and pathological stage in these three sets. The prognoses of younger patients (\<60 years) and of patients at earlier pathological stages of ccRCC were significantly improved compared with those of older patients (≥60 years) (training set, P=3.69×10^−3^; validation set, P=3.90×10^−2^; entire set, P=4.24×10^−4^) and of patients with later pathological stages (training set, P=2.44×10^−15^; validation set, P=1.31×10^−10^; entire set, P=2.00×10^−16^), respectively, which was consistent with current clinical practice ([@b39-ol-0-0-11780]).

#### Establishment of nomogram survival model integrating 10 mRNA expression risk scores with independent prognostic factors

A composite nomogram was constructed using the entire set to further assess associations between prognosis and age, pathological stage and mRNA expression. [Fig. 6A](#f6-ol-0-0-11780){ref-type="fig"} shows the nomogram of combined age, pathological stage and mRNA expression model risk score status to predict the survival of patients with ccRCC as the 'total points' axis of the sixth row. Total points represent the total account of points of age, pathological stage and mRNA expression model risk score. Calibration curves revealed good consistency between the 3- and 5-year survival probabilities of all patients of the entire set and those predicted by the nomogram survival model ([Fig. 6B](#f6-ol-0-0-11780){ref-type="fig"}).

#### Identification and pathway enrichment analysis of DEG in high-and low-risk groups of entire set

The present study aimed to resolve the possible functional roles of the 10 prognostic mRNAs in ccRCC. Samples in the entire set were divided into high- and low-risk groups by applying the optimal risk score prediction model dependent on the expression levels of the 10 DEmRNAs. A total of 400 significant DEGs (including 19 downregulated and 381 upregulated genes) with FDR \<0.05 and log~2~FC \>0.263 were identified using the limma package ([Fig. 7A](#f7-ol-0-0-11780){ref-type="fig"}). An expression heatmap of the DEGs revealed distinctive expression patterns of DEGs with high and low risk scores ([Fig. 7B](#f7-ol-0-0-11780){ref-type="fig"}). Subsequently, enrichment analyses of GO biological processes and KEGG signaling pathways for these DEGs were conducted. The results revealed that 11 biological processes, such as 'inflammatory response', 'neuron differentiation' and 'acute inflammatory response', and six KEGG signaling pathways, including 'complement and coagulation cascades' and 'neuroactive ligand-receptor interactions', were significantly enriched within these DEGs ([Table IV](#tIV-ol-0-0-11780){ref-type="table"}).

Discussion
==========

Considering that aberrant expression levels of mRNAs and lncRNAs are usually associated with the occurrence and development of ccRCC ([@b2-ol-0-0-11780],[@b9-ol-0-0-11780]--[@b13-ol-0-0-11780],[@b20-ol-0-0-11780]), exploring further lncRNA/mRNA-based signatures to predict the prognosis in patients with ccRCC should be important. In the present study, a large quantity of RNA-sequencing and survival data of patients with ccRCC was downloaded, and DERs were screened between samples of patients with less favorable and favorable prognoses using models that could predict prognosis. Among the 451 DERs obtained from the training set, 404 and 47 were mRNAs and lncRNAs, respectively. Univariate and multivariate Cox regression analyses selected 44 mRNAs and 15 lncRNAs as independent prognostic factors. Furthermore, optimal combinations of 10 DEmRNAs (AGR3, CSF2, GAL3ST2, IGLL1, PLG, SAA1, SBSN, SOX2, WFDC13 and ZIC2) and 10 DElncRNAs (COL18A1-AS1, ELOVL2-AS1, LINC00189, LINC00470, LINC00652, LINC00896, MIR205HG, TCL6, TFAP2A-AS1 and UPK1A-AS1) were screened out based on the findings of the LASSO Cox regression model.

Given the important roles of risk assessment tools in estimating the probability of risk factors and detecting high-risk populations for disease entities ([@b14-ol-0-0-11780]--[@b17-ol-0-0-11780]), the present study constructed four prognostic prediction models based on the status or expression levels of the 10 DElncRNAs or 10 DEmRNAs in optimal combinations. The predictive value of the four models for ccRCC was assessed, and the results revealed that the risk score model based on the expression levels of the 10 DEmRNAs was the best predictor. Although risk assessment tools have been widely applied to the clinical prediction of various types of cancer, such as gastric cancer, hepatocellular carcinoma and prostate cancer, few are available for ccRCC ([@b11-ol-0-0-11780],[@b18-ol-0-0-11780]--[@b21-ol-0-0-11780]). The present study created a potential risk assessment tool with which to predict the prognosis in patients with ccRCC, and to explore the possible pathogenesis of ccRCC.

According to the association with different types of cancer, especially ccRCC, the 10 DEmRNAs in the optimal combination can be divided into three groups. *AGR3, CSF2, GAL3ST2, SAA1, SBSN, SOX2* and *ZIC2* in the first group are all associated with human tumors. AGR3 was originally identified as a membrane protein from breast cancer cell lines, and it has been implicated in the growth, differentiation, metastasis and survival of breast, prostate and ovarian cancer ([@b40-ol-0-0-11780]--[@b43-ol-0-0-11780]). CSF2 is an important survival, proliferation and differentiation factor of neutrophil and macrophage progenitors ([@b44-ol-0-0-11780]). CSF2 overexpression is associated with a poor prognosis in patients with urothelial carcinoma, suggesting that CSF2 may serve as an important prognosticator and a potential therapeutic target for urothelial carcinoma ([@b45-ol-0-0-11780]). GAL3ST2 functions in regulating adhesion capacity and may be associated with tumor metastasis in lung giant cells and hepatoma cancer cells, where elevated GAL3ST2 expression is be associated with higher metastatic potential ([@b46-ol-0-0-11780]). Previous studies have identified GAL3ST2 expression in a normal murine mammary gland and in two human breast cancer cell lines, and elevated expression levels in metastatic tumors ([@b47-ol-0-0-11780],[@b48-ol-0-0-11780]). SAA is an acute phase protein that may be the precursor of amyloid fibrils in reactive systemic amyloidosis ([@b49-ol-0-0-11780]) and function in cancer pathogenesis ([@b50-ol-0-0-11780]). SAA1 may be a negative prognostic factor for patients with melanoma and further studies should assess these associations in other types of cancer ([@b51-ol-0-0-11780]). *SAA1* is overexpressed in plasma from patients with non-small cell lung cancer who experience short overall survival after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors ([@b52-ol-0-0-11780]). SBSN is an epidermal differentiation marker that is detectable in several types of tumor endothelial cells ([@b53-ol-0-0-11780],[@b54-ol-0-0-11780]). SBSN expression is associated with the growth, proliferation and invasiveness of salivary gland adenoid cystic and normal small cell lung carcinoma cells, as well as glioblastoma ([@b55-ol-0-0-11780]--[@b58-ol-0-0-11780]). SOX2, a transcription factor expressed in various types of embryonic and adult stem cells, is significantly upregulated in cancer stem cells of squamous skin tumors in mice ([@b59-ol-0-0-11780]). Furthermore, SOX2 establishes a continuum between tumor initiation and progression in primary skin tumors ([@b59-ol-0-0-11780]), and its expression is required for the proliferation and anchorage-independent growth of lung and esophageal cell lines ([@b60-ol-0-0-11780],[@b61-ol-0-0-11780]). *ZIC2* belongs to a gene family that was originally identified by homology with odd-paired genes in *Drosophila*, and functions during neural development ([@b62-ol-0-0-11780]). *ZIC2* has oncogenic features and its overexpression is closely associated with the progression of cervical, epithelial ovarian and liver cancer ([@b63-ol-0-0-11780]--[@b65-ol-0-0-11780]). Although the seven genes in the first group are all associated with human tumors, their involvement in ccRCC is unknown. The second group contains only one gene, *WFDC13*. WAP domains are widely distributed and highly conserved in vertebrates and invertebrates, and they participate in diverse physiological processes, such as calcium transport, proteinase inhibition and bacterial killing ([@b66-ol-0-0-11780]). The WFDC proteins contain WAP domains and are found in vertebrates and invertebrates ([@b66-ol-0-0-11780]). WFDC2 is frequently overexpressed in epithelial ovarian cancer cells and may have potential as a therapeutic target ([@b67-ol-0-0-11780]). However, the biological function of *WFDC13* in tumor progression remains unclear. The third group contains *IGLL1* and *PLG*, which have unknown functions.

The present findings suggested that the 10 DElncRNAs of the optimal combination may be involved in the pathogenesis of ccRCC. Among the 10 DElncRNAs, COL18A1-AS1 ([@b68-ol-0-0-11780],[@b69-ol-0-0-11780]), TCL6 ([@b70-ol-0-0-11780]) and TFAP2A-AS1 ([@b71-ol-0-0-11780]) are associated with a worse survival of patients with ccRCC, in accordance with the results of the present study. Furthermore, ELOVL2-AS1, LINC00189, LINC00470, LINC00896 and MIR205HG may be associated with tumors other than ccRCC. For instance, ELOVL2-AS1 may be a progression-associated prognostic biomarker for lung squamous cell carcinoma ([@b72-ol-0-0-11780]). LINC00189 is associated with cervical cancer recurrence and may be used as a potential prognostic biomarker ([@b73-ol-0-0-11780]). Upregulated LINC00470 expression promotes the development of gastric cancer ([@b74-ol-0-0-11780]). LINC00896 expression is upregulated in human lung adenocarcinoma ([@b75-ol-0-0-11780]) and MIR205HG is differentially expressed in papillary renal cell carcinoma ([@b76-ol-0-0-11780]). However, few studies have investigated the functions of LINC00652 and UPK1A-AS1 in tumors. Despite considerable effort to determine the underlying mechanisms of lncRNAs in cancer, how they regulate gene expression remains elusive. Further studies are required to verify these prognostic DElncRNAs in ccRCC.

Functional annotations of the significant DEGs between the high- and low-risk groups of the entire set determined by the 10 DEmRNA expression risk scores according to the GO and KEGG databases may provide an ample number of candidate genes and further information regarding the pathogenesis of ccRCC. GO functional analyses of 400 DEGs were conducted, and 11 GO terms and 5 KEGG signaling pathways validated the significant enrichment of these DEGs. These genes were significantly associated with biological processes, such as 'inflammatory response', 'neuron differentiation' and 'acute inflammatory response', and participated in signaling pathways, such as 'complement and coagulation cascades' and 'neuroactive ligand-receptor interaction', suggesting potential functions for the 10 prognostic DEmRNAs in ccRCC. Further investigation of these genes may help to further clarify the pathogenesis of ccRCC. Since the present extensive bioinformatics study was based on published data, the results of the present study should be further validated *in vitro* and/or *in vivo*. Expression of these genes in ccRCC can be detected using reverse transcription PCR or the protein levels could be examined using western blotting.

In conclusion, the present study constructed risk score models based on the status or expression levels of 10 DElncRNAs or 10 DEmRNAs to predict the prognosis of patients with ccRCC, revealing that the prognostic performance of the model based on the expression levels of the 10 DEmRNAs was the most effective. The 10 prognostic DEmRNAs were mainly associated with inflammatory response-associated biological processes, complement and coagulation cascades and neuroactive ligand-receptor interaction pathways. The 10 DEmRNAs in the optimal combination may be used as potential therapeutic targets, and the present results may provide novel insights into the pathogenesis of ccRCC.
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![Identification and clustering of DERs. (A) Left panel presents the volcano map of DERs between less favorable and favorable prognoses. Pink dots represent DERs. Black dots represent non-DERs.Red horizontal and two vertical dashed lines represent FDR \<0.05 and log2FC \>0.5, respectively. Right panel presents the composition of DERs with the types and ratios on the horizontal and vertical axes, respectively. Blue and pink columns represent proportions of down- and upregulated RNAs, respectively. (B) Two-way hierarchical clustering heatmap based on the expression levels of DERs. The black and white bars represent less favorable and favorable prognostic groups, respectively. The color key (green to red) exhibits z-score of normalized and log2 transformed expression values of DEGs. The Z-score represents the number of median absolute deviation away from the median. DERs, differentially expressed RNAs; lncRNA, long non-coding RNA; FDR, false discovery rate; FC, fold change.](ol-20-03-2420-g00){#f1-ol-0-0-11780}

![Screening curves of lambda parameters and distribution graphs of coefficients of the optimal combination of (A) lncRNAs and (B) mRNAs via the Cox-PH model based on the L1-penalized regularized regression algorithm. Horizontal and vertical axes in upper graphs indicate lambda and cvl values, respectively. prof stands for profL1 function, and \$ indicates the absolute reference. Intersection of red dotted lines indicate the value of lambda when cvl is maximal. When maximal cvl values were −491.8333 and −490.4969, lambda values were 17.3155 for mRNA and 65.3960 for lncRNA, respectively. lncRNA, long non-coding RNA; cvl, cross-validation likelihood.](ol-20-03-2420-g01){#f2-ol-0-0-11780}

![Kaplan-Meier overall survival time and ROC curves of risk score models based on the status of (A) 10 lncRNAs and (B) 10 mRNAs in the training, validation, entire and EBI-validation sets. Green/blue and red/purple curves represent low and high risk groups, respectively. In the ROC curves, the black, red, green and blue lines indicate the training, validation, entire and EBI-validation sets, respectively. lncRNA, long non-coding RNA; EBI, European Bioinformatics Institute; ROC, receiver operating characteristic; AUC, area under the curve; HR, hazard ratio.](ol-20-03-2420-g02){#f3-ol-0-0-11780}

![Kaplan-Meier curves for overall survival time and ROC analysis of risk score models based on the expression levels of (A) 10 lncRNAs and (B) 10 mRNAs in the training, validation, entire and EBI-validation sets. Green/blue and red/purple curves represent the low and high risk groups, respectively. In the ROC curves, the black, red, green and blue lines indicate the training, validation, entire and EBI-validation sets, respectively. lncRNA, long non-coding RNA; EBI, European Bioinformatics Institute; ROC, receiver operating characteristic; AUC, area under the curve; HR, hazard ratio; Exprs, expression levels.](ol-20-03-2420-g03){#f4-ol-0-0-11780}

![Kaplan-Meier overall survival curves for training (left), validation (middle) and entire (right) sets by (A) age and (B) pathologic stage. (A) Black and red curves indicate \<60 and ≥60 years, respectively. (B) Black, red, blue and purple curves represent stages I, II, III and IV, respectively. HR, hazard ratio.](ol-20-03-2420-g04){#f5-ol-0-0-11780}

![Nomogram of independent prognostic factors and mRNA expression risk scores, and calibration plots for predicting 3- and 5-year survival probabilities. (A) Nomogram of independent prognostic factors and mRNA expression risk scores. Points for each variable (age, pathological stage and mRNA expression risk score) were determined in the nomogram by drawing a vertical line from the values of each variable to the 'points' line. Summed points for all variables were plotted on the 'Total Points' line and a vertical line was drawn to read the corresponding 3- and 5-year survival probabilities. (B) Calibration plots for predicting 3- and 5-year survival probabilities. Horizontal and vertical axes indicate predicted and actual 3- and 5-year probabilities of overall survival time, respectively. Red and black lines indicate predicted 3- and 5-year probabilities of overall survival time, respectively. Round points on lines represent the average survival probability at corresponding time points with upper and lower bars indicating upper and lower standard deviations. Grey line represents ideal agreement between predicted and actual probabilities of overall survival time. exprs, expression; RS status, risk score status.](ol-20-03-2420-g05){#f6-ol-0-0-11780}

![Volcano plot and expression heatmap of DEGs between high and low risk in the entire set. (A) Volcano plot of log2FC vs. -log10FDR. Pink and black dots represent significant and non-significant DEGs, respectively. Two vertical dashed lines indicate log2FC 0.263; horizontal dashed line indicates FDR =0.05. (B) Expression heatmap of DEGs with high or low risk scores. Colored bar (green to red) on right margin indicates z-score of normalized and log2 transformed expression values of DEGs. The Z-score represents for the number of median absolute deviations away from the median. DEG, differentially expressed genes; FDR, false discovery rate; FC, fold change.](ol-20-03-2420-g06){#f7-ol-0-0-11780}

###### 

Clinical information of the samples in the training (n=263), validation (n=263) and entire sets (n=526).

  Clinical characteristics                   Training set     Testing set      Entire set
  ------------------------------------------ ---------------- ---------------- -----------------
  Age, mean ± SD                             60.84±11.73      60.24±12.52      60.54±12.12
  Sex, male/female                           171/92           171/92           342/184
  Pathological M, M0/M1/--                   213/35/15        207/42/14        420/77/29
  Pathological N, N0/N1/--                   118/8/137        120/8/135        238/16/272
  Pathological T, T1/T2/T3/T4                141/31/87/4      128/38/90/7      269/69/177/11
  Pathological stage, I/II/III/IV            137/26/61/39     126/31/62/44     263/57/123/83
  Pathological grade, G1/G2/G3/G4/--         8/110/104/37/4   5/116/101/37/4   13/226/205/74/8
  Platelet count elevated/low/normal/--      17/25/169/52     19/20/186/38     36/45/355/90
  Serum calcium, elevated/low/normal/--      4/96/75/88       6/107/72/78      10/203/147/166
  White cell count, elevated/low/normal/--   79/5/124/55      83/3/139/38      162/8/263/93
  Death, dead/alive                          86/177           86/177           172/354
  Overall survival time, months ± SD         44.88±32.63      45.41±33.05      45.15±32.81

T, tumor; N, node; M, metastasis.

###### 

Detailed information of the optimal combinations of 10 DElncRNAs or 10 DEmRNAs.

  RNA             Coefficient   P-value       HR       95% CI           Cut-off
  --------------- ------------- ------------- -------- ---------------- ---------
  mRNA                                                                  
    AGR3          0.0148287     9.65×10^−3^   1.2059   1.0465--1.3895   −0.13
    CSF2          0.0042776     9.22×10^−5^   1.4426   1.2005--1.7334   0.40
    GAL3ST2       0.0076842     1.69×10^−2^   1.3308   1.0527--1.6822   0.51
    IGLL1         0.0045121     2.50×10^−3^   1.2333   1.0765--1.4130   0.41
    PLG           −0.008533     1.88×10^−3^   0.7408   0.6131--0.8951   −0.67
    SAA1          0.0193154     1.28×10^−4^   1.8849   1.3629--2.6068   0.62
    SBSN          0.0155634     9.34×10^−3^   1.2852   1.0636--1.5528   0.55
    SOX2          0.0011085     2.76×10^−4^   1.3625   1.1533--1.6097   0.28
    WFDC13        0.0011551     2.06×10^−4^   1.3922   1.1690--1.6581   0.65
    ZIC2          0.0358394     1.43×10^−2^   1.2846   1.0512--1.5698   0.42
  lncRNA                                                                
    COL18A1-AS1   −0.058594     2.02×10^−3^   0.8678   0.7790--0.9668   0.07
    ELOVL2-AS1    0.0155223     2.75×10^−2^   1.0463   1.0056--1.1106   −0.06
    LINC00189     0.0112113     1.61×10^−2^   1.0769   1.0011--1.1701   −0.02
    LINC00470     0.036526      3.48×10^−2^   1.0574   1.0056--1.1461   −0.23
    LINC00652     0.0190087     4.50×10^−2^   1.1313   1.0927--1.3806   0.07
    LINC00896     0.0707072     2.65×10^−2^   1.0775   1.0060--1.1875   0.83
    MIR205HG      0.0209242     4.94×10^−2^   1.0344   1.0019--1.0952   0.04
    TCL6          −0.081477     1.39×10^−2^   0.9224   0.8453--0.9964   −0.13
    TFAP2A-AS1    0.0910578     9.28×10^−3^   1.1224   1.0019--1.2574   0.46
    UPK1A-AS1     0.015775      1.66×10^−2^   1.0481   1.0039--1.1053   0.20

DElncRNA, differentially expressed long non-coding RNA; HR, hazard ratio; AGR3, anterior gradient 3; CSF2, colony stimulating factor 2; GAL3ST2, galactose-3-O-sulfotransferase 2; IGLL1, immunoglobulin lambda like polypeptide 1; PLG, plasminogen; SAA1, serum amyloid A1; SBSN, suprabasin; SOX2, SRY-box transcription factor 2;WFDC13, WAP four-disulfide core domain 13; ZIC2, Zic family member 2; COL18A1-AS1, collagen antisense RNA 1; ELOVL2-AS1, elongation of very long-chain fatty acid 2 antisense RNA 1; LINC, long intergenic non-protein coding RNA; MIR205HG, microRNA 205 host gene; TCL6, T cell leukemia/lymphoma 6; TFAP2A-AS1, transcription factor AP-2 alpha antisense RNA 1; UPK1A-AS1, uroplakin 1A antisense RNA 1.

###### 

Independent prognostic clinical factors identified by univariate and multivariate Cox regression analysis.

  A, Training set (n=263)                                                                                                      
  ---------------------------------------------- ------------------------- --------------------------- ----------------------- -------------
  Age, \<60/≥60 years                            1.028 (1.009--1.047)      3.12×10^−3^                 1.026 (1.0032--1.049)   2.48×10^−2^
  Sex, male/female                               1.186 (0.755--1.862)      4.59×10^−1^                   --                    --
  Pathological M, M0/M1/--                       4.396 (0.782--6.945)      4.25×10^−1^                   --                    --
  Pathological N, N0/N1/--                       3.007 (0.779--7.670)      1.55×10^−1^                   --                    --
  Pathological T, T1/T2/T3/T4                    2.170 (1.701--2.767)      1.71×10^−11^                1.761 (0.952- 2.279)    3.02×10^−1^
  Pathological stage, I/II/III/IV/--             1.995 (1.657--2.403)      2.44×10^−15^                1.759 (1.179--2.627)    5.69×10^−3^
  Neoplasm histologic grade, G1/G2/G3/G4/--      2.536 (1.893--3.397)      1.28×10^−10^                1.361 (0.952--1.945)    9.07×10^−2^
  Platelet count, elevated/low/normal/--         0.629 (0.517--0.765)      1.10×10^−6^                 0.832 (0.679--1.017)    7.30×10^−2^
  Serum calcium, elevated/low/normal/--          1.179 (0.738--1.884)      4.90×10^−1^                   --                    --
  White cell count, elevated/low/normal/--       1.159 (0.899--1.496)      2.54×10^−1^                   --                    --
  mRNA expression model                                                                                                        
  Risk score status, high/low                    4.315 (2.611--7.132)      5.37×10^−10^                2.626 (1.426--4.838)    1.95×10^−3^
                                                                                                                               
  **B, Validation set (n=263)**                                                                                                
                                                                                                                               
                                                 **Univariate analysis**   **Multivariate analysis**                           
                                                                                                                               
  **Clinical characteristics**                   **HR (95% CI)**           **P-value**                 **HR (95% CI)**         **P-value**
                                                                                                                               
  Age, \<60/≥60 years                            1.028 (1.011--1.046)      1.41×10^−3^                 1.034 (1.013--1.055)    1.35×10^−3^
  Sex, male/female                               0.755 (0.491--1.162)      2.00×10^−1^                 --                      --
  Pathological M, M0/M1/--                       4.189 (2.710--6.475)      5.41×10^−2^                 --                      --
  Pathological N, N0/N1/--                       3.947 (1.649--9.450)      8.72×10^−2^                 --                      --
  Pathological T, T1/T2/T3/T4                    1.725 (1.375--2.164)      1.1-x10^−6^                 0.716 (0.474--1.082)    1.13×10^−1^
  Pathological stage, I/II/III/IV/--             1.786 (1.481--2.154)      1.31×10^−10^                2.006 (1.424--2.825)    6.84×10^−5^
  Neoplasm histologic grade, G1/G2/G3/G4/--      2.075 (1.557--2.765)      3.37×10^−7^                 1.245 (0.906--1.712)    1.76×10^−1^
  Platelet qualitative, elevated/low/normal/--   0.602 (0.453--0.8001)     3.07×10^−4^                 0.749 (0.560--1.001)    5.04×10^−2^
  Serum calcium, elevated/low/normal/--          0.752 (0.477--1.186)      2.20×10^−1^                 --                      --
  White cell count, elevated/low/normal/--       1.116 (0.879--1.416)      3.68×10^−1^                 --                      --
  mRNA expression model                                                                                                        
  Risk score status, high/low                    2.816 (1.746--4.542)      9.17×10^−6^                 1.986 (1.168-.379)      1.14×10^−2^
                                                                                                                               
  **C, Entire set (n=526)**                                                                                                    
                                                                                                                               
                                                 **Univariate analysis**   **Multivariate analysis**                           
                                                                                                                               
  **Clinical characteristics**                   **HR (95% CI)**           **P-value**                 **HR (95% CI)**         **P-value**
                                                                                                                               
  Age, \<60/≥60 years                            1.028 (1.015--1.041)      1.25×10^−5^                 1.022 (1.001--1.0429)   3.59×10^−2^
  Sex, male/female                               0.943 (0.692--1.287)      7.13×10^−1^                   --                    --
  Pathological M, M0/M1/--                       4.270 (0.919--5.845)      6.32×10^−2^                   --                    --
  Pathological N, N0/N1/--                       3.461 (1.836--6.526)      4.38×10^−5^                 1.007 (0.429--2.361)    9.87×10^−1^
  Pathological T, T1/T2/T3/T4                    1.914 (1.624--2.255       4.44×10^−16^                0.703 (0.451--1.098)    1.22×10^−1^
  Pathological stage, I/II/III/IV/--             1.884 (1.652--2.15)       2.00×10^−16^                1.815 (1.278--2.577)    8.68×10^−4^
  Neoplasm histological grade, G1/G2/G3/G4/--    2.285 (1.863--2.802)      3.33×10^−16^                1.359 (0.9591.926)      8.39×10^−2^
  Platelet qualitative, elevated/low/normal/--   0.648 (0.552--0.763)      1.02×10^−7^                 0.746 (0.594--0.936)    1.12×10^−2^
  Serum calcium levels, elevated/low/normal/--   0.938 (0.677--1.298)      6.98×10^−1^                   --                    --
  White cell count, elevated/low/normal/--       1.135 (0.954--1.351)      1.53×10^−1^                   --                    --
  mRNA expression model                                                                                                        
  Risk score status, high/low                    3.513 (2.486--4.964)      3.04×10^−14^                2.943 (1.666--5.200)    2.02×10^−4^

HR, hazard ratio; T, tumor; N, node; M, metastasis.

###### 

GO biological processes and KEGG pathways significantly enriched by the differentially expressed genes.

  Term                                                       Count   P-value
  ---------------------------------------------------------- ------- -------------
  Biological processes                                               
    GO:0006953 acute-phase response                          11      5.25×10^−9^
    GO:0007586 digestion                                     13      3.08×10^−7^
    GO:0002526 acute inflammatory response                   13      6.99×10^−7^
    GO:0030182 neuron differentiation                        27      1.08×10^−6^
    GO:0035270 endocrine system development                  10      1.04×10^−5^
    GO:0051606 detection of stimulus                         11      1.49×10^−4^
    GO:0007398 ectoderm development                          14      2.25×10^−4^
    GO:0030900 forebrain development                         12      2.85×10^−4^
    GO:0006954 inflammatory response                         18      3.73×10^−4^
    GO:0032101 regulation of response to external stimulus   12      4.19×10^−4^
    GO:0009611 response to wounding                          24      5.40×10^−4^
  KEGG pathways                                                      
    hsa04080: Neuroactive ligand-receptor interaction        17      1.07×10^−5^
    hsa00590: Arachidonic acid metabolism                    5       1.80×10^−2^
    hsa00591: Linoleic acid metabolism                       4       1.35×10^−2^
    hsa04060: Cytokine-cytokine receptor interaction         10      4.62×10^−2^
    hsa00592: alpha-Linolenic acid metabolism                3       4.11×10^−2^
    hsa04610: Complement and coagulation cascades            5       3.55×10^−2^

'Count' represents the number of genes significantly enriched in a biological process or pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: Contributed equally
